Predicting the emetic liability of novel chemical entities: A comparative study

British Journal of Pharmacology

Volumn 165, Issue 6, 2012, Pages 1848-1867

  Du Sert, Nathalie Percie ^a,b   Holmes, Anthony M ^a   Wallis, Rob ^c   Andrews, Paul L R ^b  

^a National Centre for the Replacement   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c PFIZER INC   (United States)

Author keywords

dog; emesis; emetic liability; ferret; human; nausea; pica; rat; vomiting

Indexed keywords

APOMORPHINE; CHOLECYSTOKININ OCTAPEPTIDE; CISPLATIN; COPPER SULFATE; CYCLOPHOSPHAMIDE; IPECAC; LITHIUM CHLORIDE; MORPHINE; NICOTINE; ROLIPRAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; DRUG DOSE INCREASE; EXPERIMENTAL DOG; EXPERIMENTAL RAT; FERRET; HUMAN; IN VIVO STUDY; INCIDENCE; LATENT PERIOD; MEDICAL RESEARCH; NAUSEA; NONHUMAN; PICA; PREDICTIVE VALUE; PRIORITY JOURNAL; PUBLICATION; QUANTITATIVE STUDY; RAT; SENSITIVITY ANALYSIS; SPECIES COMPARISON; SYSTEMATIC REVIEW; VOMITING;

ANIMALS; DOGS; EMETICS; FERRETS; HUMANS; RATS; VOMITING;

EID: 84857488262     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01669.x     Document Type: Article

References (47)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Andrews PLR, Davis CJ, (1995). Physiology of emesis induced by anti-cancer therapy. In:, Reynolds J, Andrews PL, Davis CJ, (eds). Serotonin and the Scientific Basis of Anti-Emetic Therapy. Oxford Clinical Communications: Oxford, pp. 25-49.
3. Andrews PLR, Horn CC, (2006). Signals for nausea and emesis: implications for models of upper gastrointestinal diseases. Auton Neurosci 125: 100-115.
4. Billig I, Yates BJ, Rinaman L, (2001). Plasma hormone levels and central c-Fos expression in ferrets after systemic administration of cholecystokinin. Am J Physiol Regul Integr Comp Physiol 281: R1243-R1255.
5. Borison HL, (1989). Area postrema: chemoreceptor circumventricular organ of the medulla oblongata. Prog Neurobiol 32: 351-390.
6. Brioni JD, Decker MW, Sullivan JP, Arneric SP, (1997). The pharmacology of (-)-nicotine and novel cholinergic channel modulators. Adv Pharmacol 37: 153-214.
7. Carpenter DO, Briggs DB, Knox AP, Strominger N, (1988). Excitation of area postrema neurons by transmitters, peptides, and cyclic nucleotides. J Neurophysiol 59: 358-369.
8. Christie DA, Tansey EM, (eds) (2007). The Discovery, Use and Impact of Platinum Salts As Chemotherapy Agents for Cancer. Wellcome Witnesses to Twentieth Century Medicine: London.
9. Davis CJ, Harding RK, Leslie RA, Andrews PLR, (1986). The organisation of vomiting as a protective reflex: a commentary on the first day's discussions. In:, Davis CJ, Lake-Bakaar GV, Grahame-Smith DG, (eds). Nausea and Vomiting: Mechanisms and Treatment. Springer-Verlag: Berlin, pp. 78-93.
10. Davis TG, Peterson JJ, Kou JP, Capper-Spudich EA, Ball D, Nials AT, et al,. (2009). The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tet rahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity. J Pharmacol Exp Ther 330: 922-931.
11. European Medicines Agency (2006). Guideline on Non-Clinical and Clinical Development of Medicinal Products for the Treatment of Nausea and Vomiting Associated with Cancer Chemotherapy. CPMP/EWP/4937/03. EMEA: London.
12. Hawthorn J, Andrews PLR, Ang VT, Jenkins JS, (1988). Differential release of vasopressin and oxytocin in response to abdominal vagal afferent stimulation or apomorphine in the ferret. Brain Res 438: 193-198.
13. Holmes AM, Rudd JA, Tattersall FD, Aziz Q, Andrews PLR, (2009). Opportunities for the replacement of animals in the study of nausea and vomiting. Br J Pharmacol 157: 865-880.
14. Karniol IG, Dalton J, Lader MH, (1978). Acute and chronic effects of lithium chloride on physiological and psychological measures in normals. Psychopharmacology (Berl) 57: 289-294.
15. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG, (2010). Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 8: e1000412.
16. Koch KL, Stern RM, Summy-Long J, Bingaman S, Sperry N, (1989). Gastric dysrhythmias precede activation of vasopressinergic pathways during vection-induced nausea in man. J Gastrointest Mot 1: 53.
17. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, et al,. (2006). American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24: 2932-2947.
18. Laffan RJ, Borison HL, (1957). Emetic action of nicotine and lobeline. J Pharmacol Exp Ther 121: 468-476.
19. Lang IM, Marvig J, Sarna SK, (1988). Comparison of gastrointestinal responses to CCK-8 and associated with vomiting. Am J Physiol 254: G254-G263.
20. Lee A, (2007). Adverse Drug Reactions, 2nd edn. Pharmaceutical Press: London.
21. Manno BR, Manno JE, (1977). Toxicology of ipecac: a review. Clin Toxicol 10: 221-242.
22. Masi G, Milone A, Manfredi A, Pari C, Paziente A, Millepiedi S, (2009). Effectiveness of lithium in children and adolescents with conduct disorder: a retrospective naturalistic study. CNS Drugs 23: 59-69.
23. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
24. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A, (2002). Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303: 791-804.
25. Moher D, Liberati A, Tetzlaff J, Altman DG, (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
26. Mori F, Perez-Torres S, De Caro R, Porzionato A, Macchi V, Beleta J, et al,. (2010). The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D. J Chem Neuroanat 40: 36-42.
27. Osinski MA, Uchic ME, Seifert T, Shaughnessy TK, Miller LN, Nakane M, et al,. (2005). Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets. Pharmacol Biochem Behav 81: 211-219.
28. Percie du Sert N, Rudd JA, Moss R, Andrews PL, (2009). The delayed phase of cisplatin-induced emesis is mediated by the area postrema and not the abdominal visceral innervation in the ferret. Neurosci Lett 465: 16-20.
29. Percie du Sert N, Rudd JA, Apfel CC, Andrews PL, (2011). Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT(3) receptor antagonists. Cancer Chemother Pharmacol 67: 667-686.
30. Pugsley MK, Authier S, Curtis MJ, (2008). Principles of safety pharmacology. Br J Pharmacol 154: 1382-1399.
31. Roila F, Hesketh PJ, Herrstedt J, (2006). Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17: 20-28.
32. Rowe JW, Shelton RL, Helderman JH, Vestal RE, Robertson GL, (1979). Influence of the emetic reflex on vasopressin release in man. Kidney Int 16: 729-735.
33. Rudd JA, Andrews PLR, (2005). Mechanisms of acute and delayed nausea and vomiting induced by anticancer therapies. In:, Hesketh P, (ed.). Management of Nausea and Vomiting in Cancer and Cancer Treatment. Jones and Bartlett Publishers, Inc.: Sudbury, MA, pp. 15-66.
34. Rudd JA, Naylor RJ, (1995). Opioid receptor involvement in emesis and anti-emesis. In:, Reynolds DJ, Andrews PLR, Davis CJ, (eds). Serotonin and the Scientific Basis of Anti-Emetic Therapy. Oxford Clinical Communications: Oxford, pp. 208-221.
35. Rudd JA, Yamamoto K, Yamatodani A, Takeda N, (2002). Differential action of ondansetron and dexamethasone to modify cisplatin-induced acute and delayed kaolin consumption ('pica') in rats. Eur J Pharmacol 454: 47-52.
36. Sam TS, Chan SW, Rudd JA, Yeung JH, (2001). Action of glucocorticoids to antagonise cisplatin-induced acute and delayed emesis in the ferret. Eur J Pharmacol 417: 231-237.
37. Sanger GJ, Holbrook JD, Andrews PL, (2011). The translational value of rodent gastrointestinal functions: a cautionary tale. Trends Pharmacol Sci 32: 402-409.
38. Seymour MT, (1993). The pharmacokinetics and pharmacodynamics of chemotherapeutics agents. In:, Andrews PLR, Sanger GJ, (eds). Emesis in Anti-Cancer Therapy. Chapman & Hall: London, pp. 9-45.
39. Souness JE, Rao S, (1997). Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 9: 227-236.
40. Stables R, Andrews PLR, Bailey HE, Costall B, Gunning SJ, Hawthorn J, et al,. (1987). Antiemetic properties of the 5HT3-receptor antagonist, GR38032F. Cancer Treat Rev 14: 333-336.
41. Stern RM, Koch KL, Andrews PLR, (2011). Nausea, Mechanisms andManagement. Oxford University Press: New York, pp. 171-239.
42. Wang SC, Borison HL, (1951). Copper sulphate emesis; a study of afferent pathways from the gastrointestinal tract. Am J Physiol 164: 520-526.
43. Wang SC, Borison HL, (1952). A new concept of organization of the central emetic mechanism: recent studies on the sites of action of apomorphine, copper sulfate and cardiac glycosides. Gastroenterology 22: 1-12.
44. Wilkens EP, Yates BJ, (2005). Pretreatment with ondansetron blunts plasma vasopressin increases associated with morphine administration in ferrets. Anesth Analg 101: 1029-1033. table of contents.
45. Wondergem J, Siddik ZH, Strebel FR, Bull JM, (1993). Effect of whole body hyperthermia on cis-diamminedichloroplatinum (II)-induced antitumour activity and tissue Pt-distribution: do anaesthetics influence the therapeutic ratio? Eur J Cancer 29A: 549-554.
46. Yamamoto K, Asano K, Matsukawa N, Imaizumi M, Yamatodani A, (2011). Time-course analysis of pica in rats using an automatic feeding monitoring system. J Pharmacol Toxicol Methods 63: 30-34.
47. Yung CY, (1984). A review of clinical trials of lithium in medicine. Pharmacol Biochem Behav 21 (Suppl. 1): 51-55.